Ava fertility bracelet could detect pregnancy
November 7, 2017
The Ava fertility cycle-tracking bracelet could also be used for pregnancy detection, according to researchers at the University Hospital of Zurich.
The results from a recent clinical study indicate that the device's sensor technology has potential for future use in pregnancy detection.
In the trial, the bracelet from Swiss company Ava captured physiological changes known to occur in early pregnancy. More specifically, it showed significant differences in heart rate variability, pulse rate and temperature between the late luteal phase in conceptive and non-conceptive cycles.
Based on these findings, researchers concluded that Ava could potentially be able to show the users in the future an indicator of pregnancy based on the changes of the physiological parameters reported at the late luteal phase. These findings were presented last week at ASRM in San Antonio, Texas.
"Our findings could pave the way for the continuous assessment of the occurrence of pregnancy without any effort from the user and consequently add an innovative option for early pregnancy detection," said Ava co-founder Peter Stein.
Launched to the public in July 2016, Ava's cycle tracking bracelet has proven a popular option for women hoping to optimise their chances of conception by more precisely determining the fertile window. To date, the bracelet has helped more than 1000 women conceive and Ava users from across the USA and Europe are reporting about 15 pregnancies a day. This development opens the door to a broader opportunity for the bracelet's technology to span a wider variety of women's health and wellness applications.
"We're excited about this research because it fits in with our long-term vision, which has always been for Ava to become lasting companion for women, giving them data-driven and scientifically proven insights along all stages of their reproductive lives," said Ava co-founder Lea von Bidder. "This is another step in that direction."
Founded in Switzerland in 2014 by Pascal Koenig, Philipp Tholen, Peter Stein and Lea von Bidder, Ava is a medical technology company dedicated to bringing innovation to women's reproductive health. The bracelet is the company's first consumer product. It uses sensor technology combined with clinically tested data science to detect a woman's entire fertile window in real time. Backed by $12.3m in seed and series A funding, Ava has operations in Zurich and San Francisco.